Making sure patients continue to get the medicines they need is of upmost importance as we negotiate the UK’s withdrawal from the EU.
As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.
The Association of the British Pharmaceutical Industry (ABPI) - representing leading global pharmaceutical businesses in the UK - have welcomed the EU Council's agreement to progress Brexit negotiations to the next phase and the EU Council's approval of a transition period.
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
The UK government have today published a White Paper detailing their position on ‘The Future Relationship between the United Kingdom and the European Union’.
Responding to a new House of Commons Health and Social Care Select Committee report ‘Brexit – Medicines, Medical Devices and Substances of Human Origin’, the trade associations representing the UK's pharmaceutical and biotech industries have issued a joint response backing the Committee's...
UK Marketing Authorisation Holders urged to register with SecurMed UK
The ABPI has responded to the Prime Minister's ‘Road to Brexit’ speech today at Mansion House.
Last week, the EMA announced it has completed the reallocation of the medicines for which the UK's national regulator - the MHRA - is currently rapporteur or co-rapporteur appointed by the scientific committees to coordinate the evaluation of a medicine.
The ABPI and BIA have submitted a joint submission in response to the MHRA and DHSC consultation on 'no deal' contingency legislation for medicines and devices regulation for the UK.